Clinical trials: Diabetes Type I
Type 1 or Type 2 Diabetes
Evaluate the Safety and Efficacy of Sinocare CGM System Regarding Real Time Glucose Level Monitoring
From Jan 2022 to June 2022, 120 subjects (22-75 years of age, mean ±standard deviation [SD] of 53.20 ±14.49 years) with type 1 or type 2 diabetes participated in the study in P.R. China.
- Trial name
- NCT05995756
- Where
- 3 sites in China
- Volunteers
- 120 people
- Sponsor
- Sinocare
Type 1 Diabetes Mellitus
Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of subcutaneously administered teplizumab in adults with relatively recent onset T1DM, greater than 12 weeks and…
- Trial name
- SUBCUE (NCT01189422)
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus
This trial was conducted in Europe. The aim of this trial was to compare the pharmacodynamic (the effect of the investigated drug on the body) response of insulin degludec (insulin 454) with insulin glargine at steady-state…
- Trial name
- NCT01868529
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
Healthy, Diabetes
A Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0123-0338 in Healthy Subjects and in Subjects With Type 1 Diabetes Mellitus
This trial is conducted in Europe. The purpose is to evaluate safety and tolerability of a range of single doses of subcutaneous insulin 338.
- Conditions
- Healthy, Diabetes, Diabetes Mellitus, Type 1
- Trial name
- NCT02220296
- Testing
- Insulin 338, insulin glargine
- Where
- Germany
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Immune Profile in Subjects With New Onset Type 1 Diabetes
It is hypothesized that early changes in the immune system in New Onset Type 1 Diabetes Mellitus (NOT1D) subjects can be detected in immune cells from the inguinal lymph nodes (iLN), which will be distinct from changes observed…
- Trial name
- NCT02801942
- Testing
- Inguinal lymph node fine needle aspirate biopsy, Inguinal lymph node core biopsy, Peripheral blood collection
- Where
- 2 sites in United Kingdom
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I
Treatment of Presymptomatic (Stage 1) Type 1 Diabetes Pediatric Patients With Treg Cell Preparations and Anti-CD20 Antibody
The main purpose of the study is to check: Can therapy with a preparation of regulatory cells (Tregs lymphocytes) and/or an anti-CD20 antibody preparation (rituximab) be successfully used in children with pre-diabetes to treat or…
- Conditions
- Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1
- Trial name
- PreTreg (NCT06688331)
- Testing
- ex vivo expanded CD4+CD25+CD127- regulatory T cells (Tregs), Anti-CD20 (rituximab)
- Where
- 9 sites in Poland
- Volunteers
- 150 people
- Sponsor
- PolTREG S.A.
T1D
Validation of a Computerised Adaptive Test for Measuring Caregiver Well-being
The main objective of this project is to test whether a tool (questionnaire) is suitable for assessing how caregivers of children and adolescents with TD1 feel emotionally and psychologically.
- Trial name
- NCT06999486
- Testing
- CAT well-being test
- Where
- Spain
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Adhera Health, Inc.
Diabetes Mellitus, Type 2
Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
The objective of this study is to assess the effect of the different degrees of renal impairment on the pharmacokinetics, pharmacodynamics and safety of BI10773 following oral administration of high dose BI10773 as a single dose…
- Trial name
- NCT01581658
- Testing
- BI10773
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes Mellitus
TAK-329 Glucose Clamp Study
The purpose of this study is to compare the safety, tolerability, pharmacokinetic and pharmacodynamic properties of single doses of TAK-329 with a single dose of a subcutaneously-injected rapid-acting insulin analog in…
- Trial name
- NCT01311076
- Testing
- TAK-329, Insulin
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Takeda
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine
This trial is conducted in Europe. The aim of the trial is to compare the effect of exercise on blood glucose in subjects with type 1 diabetes, who are treated with either insulin degludec (IDeg) or insulin glargine (IGlar).
- Trial name
- NCT01704417
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes
This trial is conducted in Europe and Asia. The aim of this clinical trial is to investigate the long-term safety of insulin aspart in the management of type 1 diabetes. An extension to the ANA/DCD/065 trial
- Trial name
- NCT00832182
- Testing
- insulin aspart, insulin NPH
- Where
- 10 sites in Croatia, Czechia and 3 more
- Volunteers
- 75 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Efficacy and Safety Study of DiaPep277 in Newly Diagnosed Type 1 Diabetes Adults
This study will look at the treatment effect of DiaPep277 on preservation of beta-cell function, as defined by meal-stimulated secretion of insulin.
- Trial name
- DIA-AID2 (NCT01103284)
- Testing
- DiaPep277
- Where
- 75 sites in United States, Austria and 12 more
- Volunteers
- 475 people
- Sponsor
- Andromeda Biotech Ltd.
Diabetes Mellitus, Type 2
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers
The purpose of this study is to assess the pharmacokinetic profile, safety, and tolerability of SRT2104 following administration of single and multiple oral doses (once a day for seven days) at a single dose level (2.0 g/day) to…
- Trial name
- NCT00933062
- Testing
- SRT2104
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 1, Hypoglycemia
T1 Diabetes Hypoglycemia Prevention Pilot
A single center pilot study assessing the Vigilant Diabetes Management System for the prevention of recurrent mild to moderate hypoglycemia in type I diabetes patients.
- Trial name
- NCT02682940
- Testing
- Vigilant Diabetes Management Application
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- InSpark Technologies, Inc.
Type II Diabetes
To Evaluate 24-hr Glucose After OD vs BD AZD1656
The purpose of this study is to compare the 24-hour glucose profiles in diabetic patients treated with metformin following once daily and twice daily oral dosing
- Trial name
- NCT00819884
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Advanced Solid Malignancies
An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.
To evaluate the safety, tolerability, and anti-tumor activity of the combination of durvalumab + tremelimumab or durvalumab alone in different solid tumors.
- Trial name
- STRONG (NCT03084471)
- Testing
- MEDI4736 (Durvalumab), MEDI4736 (Durvalumab) + Tremelimumab
- Where
- 79 sites in United States, Canada and 6 more
- Volunteers
- 867 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 1
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients.
- Trial name
- OPTI-2 (NCT06238778)
- Testing
- HDV-Lispro, Lispro
- Where
- 27 sites in United States
- Volunteers
- 227 people
- Sponsor
- Diasome Pharmaceuticals
Diabetes Mellitus, Type 1
A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients
The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.
- Trial name
- STRIDE (NCT06025110)
- Testing
- TCD601
- Where
- 26 sites in Belgium, Italy and 3 more
- Volunteers
- 9 people
- Sponsor
- ITB-Med LLC
Type 1 Diabetes Mellitus
Insulet Artificial Pancreas Evaluating Meal Performance and Moderate Exercise (IDE2)
To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type…
- Trial name
- IDE2 (NCT03064906)
- Testing
- Insulet AP (artificial pancreas) System
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Insulet Corporation
Type 1 Diabetes
Prevention of Severe Hypoglycaemia With Hypo-Safe Hypoglycaemia Alarm Device
Hypoglycaemia is the most common acute complication in insulin-treated diabetes. The fear of hypoglycaemia discourages diabetic subjects from the attempt to maintain tight glycemic control, which in turn leads to increased…
- Trial name
- NCT01178476
- Testing
- Hyposafe Hypoglycaemia alarm device
- Where
- Denmark
- Sponsor
- UNEEG Medical A/S
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.